

DRAFT

Application/Control Number: 10/701,844

Page 2

Art Unit: 1645

DETAILED ACTION

1. Applicant's amendment filed on 5/23/07 is acknowledged.

Examiner's amendment

2. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Elizabeth J. Haanes (see attached interview summary) on 8/2/07. The application has been amended as follows:

Claims 28 and 59 are canceled.

Claim 29. (Currently Amended) An isolated antibody or antigen-binding fragment thereof, which specifically binds to a polypeptide consisting essentially of amino acids 29-1012 of SEQ ID NO: 2.

Claim 31. (Currently Amended) The antibody or fragment thereof of claim 29, which further specifically binds to a polypeptide consisting essentially of amino acids 29-1013 of SEQ ID NO: 15.

Claim 32. (Currently Amended) The antibody or fragment thereof of claim 29, which further specifically binds to a polypeptide consisting essentially of amino acids 29-1013 of SEQ ID NO: 16.

Claim 33. (Currently Amended) The antibody or fragment thereof of claim 29, wherein said polypeptide amino acids 29-1012 of SEQ ID NO: 2 is encoded by SEQ ID NO: 1.

Claim 34. (Currently Amended) The antibody or fragment thereof of claim 29, wherein said polypeptide amino acids 29-10121013 of SEQ ID NO: 215 is encoded by SEQ ID NO: 23

23.

Claim 35. (Currently Amended) The antibody or fragment thereof of claim 29, wherein said polypeptide amino acids 29-10121013 of SEQ ID NO: 216 is encoded by SEQ ID NO: 24.

Claim 41. (Currently Amended) The antibody or fragment thereof of claim 29, which is selected from the group consisting of an Fv fragment, a single chain Fv fragment (scFv), a F(ab')2 fragment, and a Fab fragment, a single chain antibody, and a complementarity determining region (CDR).

DRAFT

Application/Control Number: 10/701,844

Page 3

Art Unit: 1645

Claim 42. (Currently Amended) The antibody or antigen-binding fragment thereof of claim 29, which further specifically binds to a polypeptide consisting essentially of an the amino acid sequence encoded by the *Chlamydia trachomatis* insert in plasmid pJJ36-J from *E. coli* TOP10 (pJJ36-J).

Claim 49. (Currently Amended) The antibody or fragment thereof of claim 42, which is selected from the group consisting of an Fv fragment, a single chain Fv fragment (scFv), a F(ab')2 fragment, and a Fab fragment, a single chain antibody, and a complementarity determining region (CDR).

Claim 50. (Currently Amended) The isolated antibody or antigen-binding fragment thereof of claim 29, which further specifically binds to a polypeptide consisting essentially of an the amino acid sequence at least 95% identical to the amino acid sequence encoded by the *Chlamydia trachomatis* insert in plasmid pAH342 from *E. coli* BL21 (pAH342).

Claim 57. (Previously PresentedCurrently Amended) The antibody or fragment thereof of claim 50, which is selected from the group consisting of an Fv fragment, a single chain Fv fragment (scFv), a F(ab')2 fragment, and a Fab fragment, a single chain antibody, and a complementarity determining region (CDR).

Claim 58. (Currently Amended) An antiserum comprising The antibody or fragment thereof of claim 29-36, which wherein said antiserum is produced by a method comprising (1) administering to an animal a polypeptide consisting essentially of an the amino acids 29-1012 of SEQ ID NO: 2 and (2) recovering the antiserum said antibody or fragment thereof from said animal.

3. In view of amendment to the claims, all the rejections of record are withdrawn.

Conclusion

4. Claims 29, 31-4242, 44-50, and 44-52-58 are allowed and have been renumbered as 1-27 respectively.

5. IDS filed on 8/1/07 is acknowledged and a signed copy the same is attached to this action.

6. Claims are drawn to an antibody that binds to amino acids 29-1012 of SEQ.ID.NO:2, said sequence is from Chlamydia trachomatis serovar LGV L2. The antibody also binds to other serovar B and F, represented by SEQ.ID.NO:15 and 16 respectively. The antibody is of use in identifying Chlamydia trachomatis.

7. Papers related to this application may be submitted to Group 1600, AU 1645 by facsimile transmission. Papers should be transmitted via the PTO Fax Center, which receives transmissions 24 hours a day and 7 days a week. The transmission of such papers by facsimile must conform to the notice published in the Official Gazette, 1096 OG 30, November 15, 1989. The Right Fax number is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through

DRAFT

Application/Control Number: 10/701,844

Page 4

Art Unit: 1645

Private PAIR only. For more information about the PMR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PMR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Padma Baskar Ph.D., whose telephone number is ((571) 272-0853. A message may be left on the Examiner's voice mail system. The Examiner can normally be reached on Monday to Friday from 6.30 a.m. to 4.00 p.m. except First Friday of each bi-week.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew can be reached on (571) 272-0787. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-1600.

Padma Baskar Ph.D.

CLEAN COPY OF ALLOWED CLAIMS

Claim 29. An isolated antibody or antigen-binding fragment thereof which specifically binds to amino acids 29-1012 of SEQ ID NO: 2.

Claim 31. The antibody or fragment thereof of claim 29, of which further specifically binds to amino acids 29-1013 of SEQ ID NO: 15.

Claim 32. The antibody or fragment thereof of claim 29, which further specifically binds to amino acids 29-1013 of SEQ ID NO: 16.

Claim 33. The antibody or fragment thereof of claim 29, wherein amino acids 29-1012 of SEQ ID NO: 2 is encoded by SEQ ID NO: 1.

Claim 34. The antibody or fragment thereof of claim 29, wherein amino acids 29-10121013 of SEQ ID NO: 215 is encoded by SEQ ID NO: 23
23.

Claim 35. The antibody or fragment thereof of claim 2932 wherein amino acids 29-10121013 of SEQ ID NO: 216 is encoded by SEQ ID NO: 24.

Claim 36. The antibody or fragment thereof of claim 29, which is polyclonal.

DRAFT

Application/Control Number: 10/701,844

Page 5

Art Unit: 1645

Claim 37. The antibody or fragment thereof of claim 29, which is monoclonal.

Claim 38. The antibody or fragment thereof of claim 29, which is humanized.

Claim 39. The antibody or fragment thereof of claim 29, which is chimeric.

Claim 40. The antibody or fragment thereof of claim 29, which is fully human.

Claim 41. The antibody or fragment thereof of claim 29, which is selected from the group consisting of a single chain Fv fragment (scFv), a F(ab')2 fragment, and a Fab fragment.

Claim 42. The antibody or antigen-binding-fragment thereof of claim 29, which further specifically binds to the amino acid sequence encoded by the *Chlamydia trachomatis* insert in plasmid pJJ36-J from *E. coli* TOP10 (pJJ36-J).

Claim 44. The antibody or fragment thereof of claim 42, which is polyclonal.

Claim 45. The antibody or fragment thereof of claim 42, which is monoclonal.

Claim 46. The antibody or fragment thereof of claim 42, which is humanized.

Claim 47. The antibody or fragment thereof of claim 42, which is chimeric.

Claim 48. The antibody or fragment thereof of claim 42, which is fully human.
~~The antibody or fragment thereof of claim 50, which is polyclonal.~~

Claim 49. The antibody or fragment thereof of claim 42, which is selected from the group consisting of a single chain Fv fragment (scFv), a F(ab')2 fragment, and a Fab fragment.

Claim 50. The isolated antibody or antigen-binding-fragment thereof of claim 29 ,which further specifically binds to the amino acid sequence encoded by the *Chlamydia trachomatis* insert in plasmid pAH342 from *E. coli* BL21 (pAH342).

Claim 53. The antibody or fragment thereof of claim 50, which is monoclonal.

Claim 54. The antibody or fragment thereof of claim 50, which is humanized.

Claim 55. The antibody or fragment thereof of claim 50, which is chimeric.

DRAFT

Application/Control Number: 10/701,844

Page 6

Art Unit: 1645

Claim 56. The antibody or fragment thereof of claim 50, which is fully human.

Claim 57. The antibody or fragment thereof of claim 50, which is selected from the group consisting of a single chain Fv fragment (scFv), a F(ab')2 fragment, and a Fab fragment.

Claim 58. (Currently Amended) The antibody or fragment thereof of claim 36,36, which is produced by a method comprising (1) administering to an animal the amino acids 29-1012 of SEQ ID NO: 2 and (2) recovering said antibody or fragment thereof from said animal.

DRAFT

Document comparison done by DeltaView on Thursday, August 02, 2007 3:30:38 PM

Input:

Document 1	file:///Q:/wpc/TEMP/Allowance.doc
Document 2	iManageDeskSite://NT-DMS3/SKGF_DC1/705291/3
Rendering set	Standard

Legend:

<u>Insertion</u>
<u>Deletion</u>
<u>Moved from</u>
<u>Moved to</u>
Style change
Format change
Moved deletion
Inserted cell
Deleted cell
Moved cell
Split/Merged cell
Padding cell

Statistics:

	Count
Insertions	29
Deletions	68
Moved from	1
Moved to	1
Style change	0
Format changed	0
Total changes	99